
WHAT IS CLAIMED IS:

1. A compound of Formula I:



(I)

wherein:

X is CR^3;

R^{1a} and R^{1b} are each independently C_{1-6} alkyl, C_{3-8} cycloalkyl, or C_{4-14} alkyl-cycloalkyl;

R^{1c} is C_{1-6} alkyl;

alternatively, ~~two of~~ R^{1a}~~,~~and R^{1b}~~, and $R^{1c}~~ are combined with the atoms to which they are attached to form a C_{3-12} heterocycloalkyl;

R^2 and R^3 are each independently hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{6-12} aryl or C_{7-18} alkyl-aryl;

R^4, R^5, R^6 and R^7 are each independently hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-OR^{8a}$, $-C(O)OR^{8b}$, C_{3-8} cycloalkyl, or C_{3-14} alkyl-cycloalkyl, wherein at least one of R^4, R^5, R^6 and R^7 is not H;

R^{8a} is C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, or C_{7-18} alkyl-aryl;


R^{8b} is H or C_{1-6} alkyl;

alternatively, R^4 and R^5, R^5 and R^6, or R^6 and R^7 are combined with the atoms to which they are each attached to form a C_{4-6} heterocycloalkyl; and

L is C_{1-6} alkylene,


or pharmaceutically acceptable salts and isotopically-labeled compounds ~~isomers~~ thereof, and

wherein the compound is other than



.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the following structure:



.

3. The compound of any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein


R^{1a}, R^{1b} and R^{1c} are each Me~~;~~

~~alternatively, two of R^{1a}, R^{1b}, and R^{1c} are combined with the atoms to which they are attached to form a C_{3-8} heterocycloalkyl~~.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein


R^2 and R^3 are each independently hydrogen, C_{1-6} alkyl, halogen, or C_{1-6} alkoxy.

5. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the following structure:




.

6. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the following structure:




.

7. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the following structure:




.

8. The compound of any one of claims 1 to 5 or 7, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the following structure:



.

9. The compound of any one of claims 1, 2, or 6, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the following structure:



.

10. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^{1a} and R^{1b} are combined with the atoms to which they are attached to form a C_{3-8} heterocycloalkyl.

~~11. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^{1a} and R^{1c} are combined with the atoms to which they are attached to form a C_{5-8} heterocycloalkyl.~~

~~12~~11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

X is CR^3;

R^{1a} and R^{1b} are each Me;

R^{1c} is Me, Et, or Pr;

R^2 is H, Me, -F, -OMe;

R^3 is H, Me, -F, or -OMe;

R^4 is H, Me, -F, -OMe or -O-benzyl;


R^5 is H, Me, -F, -Cl, -Br, -OMe, $-CF_3$, $-OCF_3$ or -O-benzyl;


R^6 is H, Me, -F, ~~$-NO_2$,~~ -OMe, $-OCF_3$, or -O-benzyl;


alternatively, R^5 and R^6 are combined to form a 1,3-dioxole ring or 1,4-dioxane ring; and


R^7 is H, Me, -F, -OMe, or -O-benzyl.


~~13~~12. The compound of claim 1, wherein the compound is





,



,



,


,



















,















,




,



,



,



,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,



N
abs
N
OMe
,

Me
N
Me
F
N
,

Me
N
Me
N
OMe
, or

Me
N
Me
OMe
N
,

N
abs
N
O
F
,

N
abs
F
N
O
,

N
abs
N
F
O
,

N
abs
N
O
F
,

N
abs
N
O
O
,

N
abs
N
O
O
,

N
abs
N
O
O
,

N
abs
N
O
,

N
abs
N
O
,













or a pharmaceutically acceptable salt thereof.


~~14~~13. The compound of claim 1, selected from the group consisting of:

























, and


or a pharmaceutically acceptable salt thereof.

~~15~~14. The compound of any one of claims 1 to ~~14~~13, wherein the compound is a salt comprising fumaric acid or a pharmaceutically acceptable salt.

~~16. A compound of Formula II:~~



~~(II)~~

~~wherein:~~

~~X is CR^3;~~

~~R^{1a} and R^{1b} are each independently C_{1-6} alkyl, C_{3-8} cycloalkyl, or C_{4-14} alkyl-cycloalkyl;~~

~~alternatively, R^{1a} and R^{1b} are combined with the atoms to which they are attached to form a C_{3-12} heterocycloalkyl;~~

~~R^2, R^3, R^4, R^5, R^6 and R^7 are each independently hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, OR^{8a}, $C(O)C(O)N(R^{8b}R^{8c})$, C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{6-12} aryl, or C_{7-18} alkyl-aryl;~~

~~R^{8a} is C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl;~~


~~R^{8b} and R^{8c} are each independently H or C_{1-6} alkyl;~~


~~alternatively, R^4 and R^5, R^5 and R^6, or R^6 and R^7 are combined with the atoms to which they are each attached to form a C_{4-6} heterocycloalkyl; and~~


~~L is C_{1-6} alkylene,~~


~~or pharmaceutically acceptable salts and isomers thereof,~~

~~wherein when R^{1a} and R^{1b} are both Me, and L is methylene, then at least one of R^2, R^3, R^4, R^5, R^6, and R^7 is not hydrogen and the compound is other than:~~





, 


, 


, 

,





, 


, 


, 

,



, 

, 

or 


;

wherein when R^{1a} and R^{1b} are Me, L is ethylene, and X is CR^3, then at least one of R^2, R^3, R^4, R^5, R^6 and R^7 is not hydrogen;

wherein when R^5 is Br, Cl, F, or C_{1-3} alkoxy, then at least one of R^2, R^3, R^4, R^6, or R^7 is not hydrogen; and


wherein when R^5 is F, then at least one of R^2, R^3, R^4, R^6, or R^7 is not hydrogen and R^6 is not F.

17. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula II has the following structure:



.


18. The compound of claim 16 or 17, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula II has the following structure:








19. The compound of any one of claims 16 to 18, or a pharmaceutically acceptable salt thereof, wherein


R^4, R^5, R^6 and R^7 are each independently hydrogen, F, Cl, -OMe, $-OCF_3$ or -O-benzyl; alternatively, R^5 and R^6 are combined with the atoms to which they are each attached to form a 1,3-dioxole ring or 1,4-dioxane ring.


20. The compound of any one of claims 16 to 19, wherein the compound is






N
N
OCF3
,


N
N
OCF3
,

O
N
N
OCF3

N
N
OMe
,

N
N
OMe
,

N
N
OMe
,





,



,



,



,



,


,


,



,


,


, or


~~or a pharmaceutically acceptable salt thereof.~~


~~21. The compound of claim 16, wherein the compound is~~



,

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 16, wherein the compound is




,

or a pharmaceutically acceptable salt thereof.

23. The compound of any one of claims 16 to 22, wherein the compound is a salt comprising fumaric acid or a pharmaceutically acceptable salt.

2415. A pharmaceutical composition comprising a compound of any one of claims 1 to 2314, and a pharmaceutically acceptable excipient.

2516. A compound of any one of claims 1 to 14 Formula I:



(I)

or a pharmaceutically acceptable salt thereof, in an amount sufficient to increase neuronal plasticity of the neuronal cell, wherein:

X is N or CR^3;

R^{1a}, R^{1b}, and R^{1c} are each independently hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, or C_{4-14} alkyl-cycloalkyl;

alternatively, two of R^{1a}, R^{1b}, and R^{1c} are combined with the atoms to which they are attached to form a C_{3-12} heterocycloalkyl;

~~R^2, R^3, R^4, R^5, R^6 and R^7 are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkylamine, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-OR^{8a}$, $-NO_2$, $-CN$, $-C(O)R^{8b}$, $-C(O)OR^{8b}$, $-OC(O)R^{8b}$, $-OC(O)OR^{8b}$, $-N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)R^{8c}$, $-C(O)N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)OR^{8c}$, $-OC(O)N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)N(R^{8c}R^{8d})$, $-C(O)C(O)N(R^{8b}R^{8c})$, $-S(O_2)R^{8b}$, $-S(O)_2N(R^{8b}R^{8c})$, C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl, C_{5-10} heteroaryl, or C_{4-16} alkyl-heteroaryl;~~

~~R^{8a} is C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl, C_{5-10} heteroaryl, or C_{4-16} alkyl-heteroaryl;~~

~~R^{8b}, R^{8c} and R^{8d} are each independently H or C_{1-6} alkyl;~~

~~alternatively, one of R^{1a}, R^{1b}, or R^{1c} is combined with R^2 to form a C_{5-12} heterocycloalkyl;~~


~~alternatively, R^2 and R^3 are combined with the atoms to which they are each attached to form a C_{4-8} cycloalkyl, C_{4-10} heterocycloalkyl, or C_{6-12} aryl;~~

~~alternatively, R^4 and R^5, R^5 and R^6, or R^6 and R^7 are combined with the atoms to which they are each attached to form a C_{3-6} cycloalkyl, C_{3-6} heterocycloalkyl, C_{6-12} aryl, or C_{5-10} heteroaryl; and~~

~~L is C_{1-6} alkylene,~~

for use in therapy.

~~26~~17. Use of a compound of any one of claims 1 to 14~~Formula I:~~



~~(I)~~

or a pharmaceutically acceptable salt thereof, in an amount sufficient to increase neuronal plasticity of the neuronal cell~~, wherein:~~

~~X is N or CR^3;~~

~~R^{1a}, R^{1b}, and R^{1c} are each independently hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, or C_{4-14} alkyl-cycloalkyl;~~

~~alternatively, two of R^{1a}, R^{1b}, and R^{1c} are combined with the atoms to which they are attached to form a C_{3-12} heterocycloalkyl;~~

~~R^2, R^3, R^4, R^5, R^6 and R^7 are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkylamine, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-OR^{8a}$, $-NO_2$, $-CN$, $-C(O)R^{8b}$, $-C(O)OR^{8b}$, $-OC(O)R^{8b}$, $-OC(O)OR^{8b}$, $-N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)R^{8c}$, $-C(O)N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)OR^{8c}$, $-OC(O)N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)N(R^{8c}R^{8d})$, $-C(O)C(O)N(R^{8b}R^{8c})$, $-S(O_2)R^{8b}$, $-S(O)_2N(R^{8b}R^{8c})$, C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl, C_{5-10} heteroaryl, or C_{4-16} alkyl-heteroaryl;~~

~~R^{8a} is C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl, C_{5-10} heteroaryl, or C_{4-16} alkyl-heteroaryl;~~

~~R^{8b}, R^{8c} and R^{8d} are each independently H or C_{1-6} alkyl;~~

~~alternatively, one of R^{1a}, R^{1b}, or R^{1c} is combined with R^2 to form a C_{5-12} heterocycloalkyl;~~


~~alternatively, R^2 and R^3 are combined with the atoms to which they are each attached to form a C_{4-8} cycloalkyl, C_{4-10} heterocycloalkyl, or C_{6-12} aryl;~~

~~alternatively, R^4 and R^5, R^5 and R^6, or R^6 and R^7 are combined with the atoms to which they are each attached to form a C_{3-6} cycloalkyl, C_{3-6} heterocycloalkyl, C_{6-12} aryl, or C_{5-10} heteroaryl; and~~

~~L is C_{1-6} alkylene,~~

in the manufacture of a medicament for increasing neuronal plasticity.

~~27~~18. Use of a compound of <u>any one of claims 1 to 14</u>~~Formula I:~~



~~(I)~~

or a pharmaceutically acceptable salt thereof, ~~thereby treating the brain disorder, wherein:~~

~~X is N or CR^3;~~

~~R^{1a}, R^{1b}, and R^{1c} are each independently hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, or C_{4-14} alkyl-cycloalkyl;~~

~~alternatively, two of R^{1a}, R^{1b}, and R^{1c} are combined with the atoms to which they are attached to form a C_{3-12} heterocycloalkyl;~~

~~R^2, R^3, R^4, R^5, R^6 and R^7 are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkylamine, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-OR^{8a}$, $-NO_2$,~~

~~-CN, -C(O)R^{8b}, -C(O)OR^{8b}, -OC(O)R^{8b}, -OC(O)OR^{8b}, -N($R^{8b}$$R^{8c}$), -N($R^{8b}$)C(O)$R^{8c}$, -C(O)N($R^{8b}$$R^{8c}$), -N($R^{8b}$)C(O)O$R^{8c}$, -OC(O)N($R^{8b}$$R^{8c}$), -N($R^{8b}$)C(O)N($R^{8c}$$R^{8d}$), -C(O)C(O)N($R^{8b}$$R^{8c}$), -S($O_2$)$R^{8b}$, -S($O_2$)N($R^{8b}$$R^{8c}$), C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl, C_{5-10} heteroaryl, or C_{4-16} alkyl-heteroaryl;~~

~~R^{8a} is C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl, C_{5-10} heteroaryl, or C_{4-16} alkyl-heteroaryl;~~

~~R^{8b}, R^{8c} and R^{8d} are each independently H or C_{1-6} alkyl;~~

~~alternatively, one of R^{1a}, R^{1b}, or R^{1c} is combined with R^2 to form a C_{5-12} heterocycloalkyl;~~

~~alternatively, R^2 and R^3 are combined with the atoms to which they are each attached to form a C_{4-8} cycloalkyl, C_{4-10} heterocycloalkyl, or C_{6-12} aryl;~~

~~alternatively, R^4 and R^5, R^5 and R^6, or R^6 and R^7 are combined with the atoms to which they are each attached to form a C_{3-6} cycloalkyl, C_{3-6} heterocycloalkyl, C_{6-12} aryl, or C_{5-10} heteroaryl; and~~

~~L is C_{1-6} alkylene,~~

in the manufacture of a medicament for treating a brain disorder.

~~28~~19. The use of claim ~~27~~18, wherein the brain disorder is a neurodegenerative disorder, Alzheimer's, or Parkinson's disease.

~~29~~20. The use of claim ~~27~~18, wherein the brain disorder is a psychological disorder, depression, addiction, anxiety, or a post-traumatic stress disorder.

~~30~~21. The use of claim ~~29~~20, wherein the brain disorder is depression.

~~31~~22. The use of claim ~~29~~20, wherein the brain disorder is addiction.


~~32~~23. The use of claim ~~27~~18, wherein the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder.

~~33~~24. The use of claim ~~27~~18, wherein the brain disorder is stroke or traumatic brain injury.

~~34~~25. The use of any one of claims ~~27~~ 18 to ~~33~~24, wherein

one or more additional therapeutic agent that is lithium, Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Ariprazole (Abilify), Ziprasidone (Geodon), ~~p~~Clozapine (Clozaril), divalproex sodium (Depakote), lamotrigine (Lamictal), valproic acid (Depakene), carbamazepine (Equetro), topiramate (Topamax), levomilnacipran (Fetzima), duloxetine (Cymbalta, Yentreve), venlafaxine (Effexor), citalopram (Celexa), fluvoxamine (Luvox), escitalopram (Lexapro), fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), clomipramine (Anafranil), amitriptyline (Elavil), desipramine (Norpramin), imipramine (Tofranil), nortriptyline (Pamelor), phenelzine (Nardil), tranylcypromine (Parnate), diazepam (Valium), alprazolam (Xanax), or clonazepam (Klonopin) is to be administered.

~~35~~26. Use of a compound of any one of claims 1-14~~Formula I:~~



~~(I)~~

or a pharmaceutically acceptable salt thereof, in an amount sufficient to increase neuronal plasticity of the neuronal cell~~, wherein:~~

~~X is N or CR^3;~~

~~R^{1a}, R^{1b}, and R^{1c} are each independently hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, or C_{4-14} alkyl-cycloalkyl;~~

~~alternatively, two of R^{1a}, R^{1b}, and R^{1c} are combined with the atoms to which they are attached to form a C_{3-12} heterocycloalkyl;~~

~~R^2, R^3, R^4, R^5, R^6 and R^7 are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{1-6} haloalkyl, C_{1-6} alkylamine, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-OR^{8a}$, $-NO_2$, $-CN$, $-C(O)R^{8b}$, $-C(O)OR^{8b}$, $-OC(O)R^{8b}$, $-OC(O)OR^{8b}$, $-N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)R^{8c}$, $-C(O)N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)OR^{8c}$, $-OC(O)N(R^{8b}R^{8c})$, $-N(R^{8b})C(O)N(R^{8c}R^{8d})$, $-C(O)C(O)N(R^{8b}R^{8c})$, $-S(O_2)R^{8b}$, $-S(O)_2N(R^{8b}R^{8c})$, C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl, C_{5-10} heteroaryl, or C_{4-16} alkyl-heteroaryl;~~

~~R^{8a} is C_{3-8} cycloalkyl, C_{3-14} alkyl-cycloalkyl, C_{4-10} heterocycloalkyl, C_{4-16} alkyl-heterocycloalkyl, C_{6-12} aryl, C_{7-18} alkyl-aryl, C_{5-10} heteroaryl, or C_{4-16} alkyl-heteroaryl;~~

~~R^{8b}, R^{8c} and R^{8d} are each independently H or C_{1-6} alkyl;~~

~~alternatively, one of R^{1a}, R^{1b}, or R^{1c} is combined with R^2 to form a C_{5-12} heterocycloalkyl;~~

~~alternatively, R^2 and R^3 are combined with the atoms to which they are each attached to form a C_{4-8} cycloalkyl, C_{4-10} heterocycloalkyl, or C_{6-12} aryl;~~

~~alternatively, R^4 and R^5, R^5 and R^6, or R^6 and R^7 are combined with the atoms to which they are each attached to form a C_{3-6} cycloalkyl, C_{3-6} heterocycloalkyl, C_{6-12} aryl, or C_{5-10} heteroaryl; and~~

~~L is C_{1-6} alkylene,~~

in the manufacture of a medicament for increasing at least one of translation, transcription or secretion of neurotrophic factors.

~~36. The compound for use or use of any one of claims 25 to 35, wherein the compound has a structure represented by a compound of any one of claims 1 to 22.~~